Introduction {#sec1}
============

A novel coronavirus \[severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\], which initially appeared in December 2019 by Wuhan in China,[@bib1] spread rapidly from China to Japan, Korea, other Asian countries, the United states of America (USA), European countries during only 3 months. The pandemic of a novel coronavirus disease (COVID-19) brought a crisis of human life and an economic burden worldwide. It is well known that SARS-CoV-2 has a high pathogenicity and therefore, COVID-19 could cause severe acute respiratory distress syndrome (ARDS), such as 13.8% cases with severe, and 6.1% with critical courses, showing a high mortality rate of 12--45% among cases with pneumonia requiring ICU admission.[@bib2] ^,^ [@bib3] It is reported that different types of SARS-CoV2 such as type A, B and C are seen in Wuhan, Japan, USA, and European countries.[@bib4] These different types of virus could show different manifestations, radiological findings and pathogenicities each other.

Currently, the diagnosis as COVID-19 was based on positive result by SARS-CoV2- reverse-transcription polymerase chain reaction (RT-PCR) with clinical manifestations which are consistent with COVID-19. While early diagnosis of COVID-19 pneumonia is important for infection control to avoid secondary transmission by airborne and aerosol, PCR testing requires 4--5 working days for the final diagnostic decision. Due to this time rag from first visit to the final diagnosis, patients suspected with COVID-19 should be kept in isolation, resulting in an increase of medical staffs' labors. Viral pneumonitis generally shows diffuse GGO such as influenza pneumonitis. For the purpose of identifying radiological features of COVID-19 pneumonia by chest CT scanning, we reviewed all cases of COVID-19 pneumonia in Japan published previously by the homepage of the Japanese Association for Infectious Diseases (<http://www.kansensho.or.jp/modules/topics/index.php?content_id=31#case_reports>), including ours. This is the first report documenting clinical manifestations and radiological features of COVID-19 pneumonia in Japan.

Patients and methods {#sec2}
====================

We present 8 COVID-19 pneumonia cases ([Table 1](#tbl1){ref-type="table"} ) that we experienced during March 2020 and April 2020 and reviewed all cases previously published by the homepage of the Japanese Association for Infectious Diseases from Feb 5 2020 until April 30 2020,[@bib5] including ours to find clinical manifestations and radiological features of chest CT findings among COVID-19 pneumonia patients.Table 1Reviewed patients' characteristics and clinical manifestations (n = 92).Table 1VariablesNumber (% except for age)Median age (range, years)66 (16--92)Male gender (%)50 (54)Smoking history Current smoker5 (5) Ex-smoker17 (18) Never smoker36 (39) Unknown34 (37)Infectious routes Cruise ship25 (27) Music club, bar, night club3 (3) Travel history6 (7) Nursing home10 (11) Sick contact28 (30) Other2 (2) Unknown21 (23)Underlying diseases (n = 90) Any60 (67) Heart disease7 (8) Chronic respiratory disease10 (11) Diabetes mellitus18 (20) Malignancy11 (12) Chronic kidney disease4 (4) Chronic hepatic disease4 (4) Hypertension32 (36) Hyperlipidemia14 (16) Cerebrovascular disease8 (9) Collagen vascular disease4 (4)Symptoms on diagnosis Fever (≧37.5 °C)66 (72) Cough37 (40) Sputum4 (4) Sorethroat15 (16) Runny nose9 (10) Dyspnea13 (14) General fatigue33 (36) Headache5 (5) Anorexia10 (11) Diarrhea10 (11) Stomachache2 (2) Consciousness disturbance2 (2) Nausea/vomit5 (5) Headache13 (14) Taste disorder5 (5) Olfactory disorder3 (3)Respiratory rate ≧22 (/min)10/69 (14)Respiratory failure \[SpO~2~\<90% (room air)\]11/90 (12)Fine crackles on ausculations10/68 (15)Treatment (n = 82) Prednisolone16 (20) Hydroxychloroquine11 (13) Lopinavir/ritonavir,28 (34) Macrolides16 (20) Neuraminidase inhibitors7 (9) Ciclesonide,26 (32) Camostat5 (6) Nafamostat2 (2) Favipiravir18 (22) Baloxavir2 (2) Kampo medicine6 (7) Sivelestat3 (4) Hemodialysis2 (2) Intravenous immunoglobulin3 (4)Intratracheal intubation and mechanical ventilation14 (17)Outcome[∗](#tbl1fnlowast){ref-type="table-fn"} (n = 65)Survival61 (94)Death4 (6)[^1][^2]

Patients' characteristics, clinical symptoms, radiological findings by chest CT images, treatment and outcome were evaluated. All cases were confirmed by real-time RT-PCR analysis of nasopharyngeal or throat swab specimens according to a standard protocol. Cases who do not have information of chest CT findings were excluded. This study was approved by the Institutional Review Board of Aichi Medical University Hospital.

Results {#sec3}
=======

A total of 92 patients from 55 case reports were enrolled in this study. [Table 1](#tbl1){ref-type="table"} shows patients' characteristics and clinical outcomes. The patients were 50 males (54%) and 42 females (46%). The median age was 66 years (16--92 years). Twenty-eight patients (30%) had a close contact with someone with COVID-19. There were no obvious history of exposure in 21 (23%).

The most frequent underlying diseases was hypertension in 32 (36%), followed by diabetes mellitus in 18 (20%). As for clinical symptoms, fever was seen the most frequently in 66 (72%), followed by cough in 37 (40%), general fatigue in 33 (36%). Radiological findings were shown in [Table 2](#tbl2){ref-type="table"} . Ground-glass opacities (GGO)s and mixed lesions with GGOs and lobular shadows were seen in 88 (96%) and 27 (29%), respectively. Neither mass shadows nor tree-in-bud appearances were seen in all patients. The predominant pattern observed was bilateral in 78 (85%), unilateral lung involvements in 14 (15%) and peripheral distribution in 76 (83%). Patchy shadows were found more frequently in 20--39 year old-patients than in others (≧40 years) (50% vs. 8%, *p* = 0.008 by Fisher\'s exact test). The mean timing for CT scan after the onset of signs and symptoms was 6.1 days. There was no correlation between the timing after the onset and any radiological features. There was no difference of timing of CT scan between bilateral and unilateral findings (6.1 vs. 6.1 days, *p* = 0.956). We could not find any correlation between the underlying diseases and the radiological features. As for the correlation between the radiological featuress and the outcomes, a diffuse pattern is more frequently seen in the death group than in the survival group even though there was no statistical difference (100% vs. 56%, *p* = 0.082). There was no correlation between other patterns and the outcomes (data not shown).Table 2Radiological features by chest CT findings.Table 2VariablesNumber (%)Tomographic features Ground-glass opacity88 (96) Mixed lesion with GGO and lobular shadow27 (29) Peripheral distribution76 (83) Diffuse60 (65) Airspace consolidation11 (12) Nodule2 (2) Patchy shadow11 (12) Cavity1 (1) Tree-in bud appearance0 Mass lesion0 Bilateral78 (85) Unilateral14 (15)[∗](#tbl2fnlowast){ref-type="table-fn"}Timepoint CT scan after onset of the symptoms and signs (mean days±SD)6.1 ± 3.5[^3][^4][^5][^6]

As for the initial treatment, lopinavir/ritonavir was used the most frequently in 28 (34%), followed by ciclesonid in 26 (32%). Favipiravir was prescribed in 18 (22%). Combination therapy with 2 more agents and no therapy were seen in 45/81 (56%) and 14/82 (17%), respectively. In terms of outcomes, 14 patients (17%) required mechanical ventilations, 61/65 (94%) were survived and 4/65 (6%) died. Twenty-eight patients moved to another institute or under treatment.

Discussion {#sec4}
==========

Typical tomographic findings of COVID-19 pneumonia are GGOs, peripheral distribution and bilateral lung involvements[@bib6] ^,^ [@bib7] as same as the result of our study. Notably, respiratory symptoms such as cough and sputum were seen in 36 (39%) and 4 (4%) respectively among the patients with COVID-19 pneumonia. Forty-three patients (47%) had no respiratory symptoms such as cough, sore throat, runny nose or dyspnea. This could be explained by that the clinical course of COVID-19 pneumonia would progress slowly in many cases, even if some cases have acute respiratory failure. Although all of coronavirus infections could cause cytokine storm, some reported that the pathophysiology of MERS and SARS-CoV differ from that of COVID-19.[@bib1] The disease severity could depend on the correlation between the host immunity and the imbalance of helper T-cell 1 and 2. Therefore, it is reasonable that some pneumonia patients improved without any therapy.[@bib1] ^,^ [@bib2] Some COVID-19 cases which were considered as light or moderate, unfortunately died. We worry that some COVID-19 patients who were misdiagnosed as not having pneumonia could develop acute respiratory failure, or cytokine release syndrome (CRS), resulting in unexpected) death**s**.

Different shadows could appear in different patients depending on the age and conditions. Immunological effect could be influenced differ in patients' ages and conditions. Some documented that predominant shadows in the right of the lung were seen among the patients. We could not find correlation between disease severity and the predominance of the lung side due to a lack of tomographic information.[@bib6]

The patients in this review were older and have more comorbidities than those in previous studies.[@bib6] ^,^ [@bib8] In this review, all patients who died were older than 75 years. Three of the patients had severe comorbidities (One had no information of underlying disease). We recommend that COVID-19 patients with risk factors who developed respiratory failure should receive chest CT scan to detect if they have pneumonia or not. While the standard treatment for COVID-19 is not yet established, the clinical trials of some promising antiviral drugs are ongoing. Early treatment for COVID-19 pneumonia could prevent the disease deterioration, resulting in favorable outcomes.

Fortunately, the mortality rate of COVID-19 in Japan is the lowest all over the world.[@bib9] This result may be attributable to the specific aspects in the Japanese healthcare system. Japanese medical service is based on a free-access policy and medical cost could be covered by a universal public insurance system for every citizen as well as for inhabitants from abroad. Thus, it is easier to perform CT scan in Japan than any other country. We believe that early diagnosis of COVID-19 pneumonia could contribute to a favor outcome. In order to reduce the risk of nosocomial infection and mortality of the disease, chest CT should be performed even though we are facing the escalation of medical costs and staff\'s labors.

There are some limitations in our study. First, this is a retrospective study in a small population. Second, this study was a case review of the literature in which clinical information might be insufficient. Third, this review has included only cases who showed positive SARD-CoV2-RT-PCR testing. Thus, these patients might not reflect the whole patients with COVID-19 pneumonia in the real world.

We concluded that COVID-19 pneumonia patients show typically GGO, peripheral, bilateral shadows in chest CT. The patients should receive chest CT if COVID-19 is suspected for the early diagnosis and therapeutic intervention, resulting in a favor outcome and prevention of secondary nosocomial transmitted infection.
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[^1]: SpO~2~, oxygen saturation.

[^2]: Twenty-seven patients moved to other institutes or under treatment.

[^3]: CT, computed tomography; GGO, ground-glass opacity; SD, standard deviation.

[^4]: There was no correlation between the date after onset and any tomographic features. We could not find the correlation between underlying disease and tomographic features.

[^5]: As for the correlation between radiological features and outcome, diffuse pattern is more frequently seen in death group than survival group even though there was no statistical difference (100% v.s. 56%, *p* = 0.082). Other patterns of CT scan.

[^6]: Timing CT scan after onset of the symptoms and signs were analyzed in 84 patients due to missing information.
